GMP Securities Research Note Induces New Round Of Cannabis Stocks Selling

Benjamin A. Smith

In an early Monday sell-side research note published this morning, cannabis stocks bulls were jarred by a less-than-enthusiastic outlook. Canadian equity research and investment bank, GMP Securities, issued a quasi-damning report on the revenue side of the legalization equation—news which certainly wasn’t supportive for sentiment change the sector so badly required.

The report delivers a comprehensive overview on how cannabis sales are materializing in major markets throughout Canada. Specifically, Ontario (Ontario Cannabis Store – OCS), Quebec (Société Québécoise du cannabis – SQDC), Alberta (Alberta Gaming and Liquor Commission -AGLC) and British Columbia (BC Liquor Distribution Branch – BCLDB). While a few kernels of optimism reside within the report (i.e. “Alberta faring well…”, it was the Page 1 “Bottom Line” which impacted the market most prevalently:

With 12 days of cannabis legalization in the rear view, it becomes increasingly clear that recreational cannabis sales in 2018 will be much lower than previously expected…. As a result, we have reduced our recreational cannabis sales expectations for 2018 for most companies under coverage.

And with bearish forecast in-hand, traders opted to sell into yet another strong beginning for cannabis stocks. This selling manifested prominently in industry leader, Canopy Growth, as a similar-sized gap-up vis-a-vis CGC and SPY evaporated within minutes on-open. Once price broke below the psychologically-important Constellation Brands rough equity buy-in levels at C$48.60 (October 25 & 26 lows), bullish hopes were dashed early.

Naturally, the entire cannabis complex followed. Particularly impacted were the more notable market laggards, such as  Aurora Cannabis and Green Organic Dutchman Holdings (TGOD). Both stocks actually gaped-down on the session, refusing to take their cues from the modest exuberance in sector/index pricing.

In TGOD’s case, the weakness is particularly notable. That’s because price dropped below its all-time low of $3.50/share, set on May 9th, just days after its IPO-debut on the Toronto Stock Exchange. With tens of millions of retail shares becoming eligible to trade after the 6-month lockup period expires on November 2nd, it remains to be seen how the stock copes with increased supply. Certainly, the steep recent drop in prices should mitigate any potential weakness to some degree; how much is debatable. It’s a narrative Midas Letter will be following closely.

On a broad market level, the Horizons Marijuana Life Sciences Index ETF (TSE:HMMJ) has now shed ↓31.78% in value since its October 15th close of $26.05/share. Even recent out-performers like Namaste Technologies and Emerald Health Therapeutics have given up promising bullish rallies.

How much today’s GMP Securities note played a hand in today’s continued selling is an open question. But certainly it didn’t help, and likely provided the impetus bottom-picking bullish investors needed to throw in the towel near-term.

Update – 1:53 pm EST

GMP Securities revised its forecast in Canopy Growth lower. “Lower industry sales of recreational marijuana than previously forecasted combined with lower market share expectations for Canopy translate into a decrease of $181m in our FY19 revenue estimates to $288m. Our revised EBITDA estimate of negative -$53m is a decrease from our previous break-even assumptions. Our FY20 forecasts remain unchanged.”

GMP Securities found, among other things, that brand preference is not major a decision factor among consumers they surveyed. Thus, they believe market capture will be closer to 20% from the 33% originally forecast.

Benjamin A. Smith

Benjamin A. Smith

Ben is a research analyst and capital markets professional with nearly 20 years of experience. His areas of expertise are broad-based, and include extensive knowledge of macro economics, stock/derivative trading, commodity complexes, cryptocurrencies and technical/quant analysis. He also maintains an particular affinity for U.S. politics and the macro-regulatory environment facing...
More Info...

[email protected] |

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.